Screener
Emergent Biosolutions EBS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
FAQ
- What is Emergent Biosolutions's total liabilities?
- Emergent Biosolutions (EBS) reported total liabilities of $12.8M in Q2 2026.
- How has Emergent Biosolutions's total liabilities changed year-over-year?
- Emergent Biosolutions's total liabilities increased by 33.3% year-over-year, from $9.6M to $12.8M.
- What is the long-term trend for Emergent Biosolutions's total liabilities?
- Over 5 years (2020 to 2025), Emergent Biosolutions's total liabilities has grown at a -21.6% compound annual growth rate (CAGR), from $73.1M to $21.7M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Emergent Biosolutions's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude